Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab

Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab

Abstract Regorafenib is a standard salvage line therapy used for advanced colorectal cancer (CRC). Recently, trifluridine/tipiracil (TFTD) plus bevacizumab also showed promising efficacy as a salvage line therapy for advanced CRC. However, the efficacy and safety of regorafenib for patients with adv...

Full description

Bibliographic Details
Main Authors: Toshihiko Matsumoto, Tatsuki Ikoma, Shogo Yamamura, Kou Miura, Takao Tsuduki, Takanori Watanabe, Hiroki Nagai, Masahiro Takatani, Hisateru Yasui
Format: Article
Language:English
Published: Nature Portfolio 2023-02-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-29706-6

Similar Items

Similar Items